Search

Author/Creator Zhou, Shuaixiang

1. Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody. Issue 1 (1st January 2020)

Authors:
Wang, Yan; Pan, Donghui; Huang, Chenrong; Chen, Bingliang; Li, Mingzhu; Zhou, Shuaixiang; Wang, Lizhen; Wu, Min; Wang, Xinyu; Bian, Yicong; Yan, Junjie; Liu, Junjian; Yang, Min; Miao, Liyan
Journal:
MAbs
Issue:
Volume 12:Issue 1(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. Issue 8 (17th November 2019)

Authors:
Wang, Jie; Fei, Keke; Jing, Hua; Wu, Zhihai; Wu, Weiwei; Zhou, Shuaixiang; Ni, Haiqing; Chen, Bingliang; Xiong, Yan; Liu, Yanpeng; Peng, Bo; Yu, Dechao; Jiang, Haiping; Liu, Junjian
Journal:
MAbs
Issue:
Volume 11:Issue 8(2019)
Page Start:
1443
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma. (28th June 2022)

Authors:
Fei, Keke; Ni, Haiqing; Zhu, Mengjia; Kuang, Zhihui; Wu, Min; Wu, Zhihai; Wang, Feifei; Zhou, Shuaixiang; Jing, Hua; Wu, Weiwei; Wu, Dongdong; Bai, Dongmei; Chen, Bingliang
Journal:
Cancer letters
Issue:
Volume 536(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗